{
    "clinical_study": {
        "@rank": "83928", 
        "brief_summary": {
            "textblock": "To compare the therapeutic efficacy of recombinant human brain natriuretic peptide (rhBNP)\n      with dobutamine on acute decompensated heart failure patients with different blood BNP\n      levels"
        }, 
        "brief_title": "A Comparison of Recombinant Human Brain Natriuretic Peptide and Dobutamine", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": "Acute Decompensated Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "detailed_description": {
            "textblock": "Patients with acute decompensated heart failure (ADHF) whose left ventricular ejection\n      fraction(LVEF) was <40%, were assigned to a high BNP group (BNP \u2264 3000 pg/mL) or an\n      extra-high BNP group (BNP > 3000 pg/mL) , depending on their admission plasma BNP levels.\n      Each group was then subdivided into rhBNP or dobutamine subgroups according to intravenous\n      administration with either rhBNP or dobutamine for 24-72h. The effects of rhBNP and\n      dobutamine on patients in the high and extra-high BNP groups were compared."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients were classified as NYHA class III-IV\n\n          -  ejection fraction <40%\n\n        Exclusion Criteria:\n\n          -  intravenous administration with rhBNP or dobutamine in the 2 weeks before study entry\n\n          -  acute myocardial infarction\n\n          -  significant valvular stenosis\n\n          -  serious ventricular arrhythmia (frequent ventricular premature beat of >5 bpm,\n             nonsustained and sustained ventricular tachycardia)\n\n          -  blood pressure <95/60 mmHg or >140/90 mmHg\n\n          -  shock\n\n          -  hypovolemia\n\n          -  hepatic or renal impairment\n\n          -  pregnant and lactating women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with acute decompensated heart failure who required hospitalization"
            }
        }, 
        "enrollment": {
            "#text": "104", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01837849", 
            "org_study_id": "AHNTU-2010-28"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dobutamine", 
                "Natriuretic Peptide, Brain"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "heart failure", 
            "rhBNP", 
            "Dobutamine"
        ], 
        "lastchanged_date": "April 18, 2013", 
        "number_of_groups": "1", 
        "official_title": "Comparative Effects of Recombinant Human Brain Natriuretic Peptide and Dobutamine on Acute Decompensated Heart Failure Patients With Different Blood BNP Levels", 
        "overall_official": {
            "affiliation": "Nantong University", 
            "last_name": "Jianhua Zhu, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "left ventricular ejection fraction (LVEF) in the High and Extra-high BNP Groups", 
                "safety_issue": "No", 
                "time_frame": "baseline and 5 days"
            }, 
            {
                "measure": "Left ventricle end diastolic dimension (LVEDD)in the High and Extra-high BNP Groups", 
                "safety_issue": "No", 
                "time_frame": "baseline and 5 days"
            }, 
            {
                "measure": "Blood BNP in the High and Extra-high BNP Groups", 
                "safety_issue": "No", 
                "time_frame": "baseline and 5 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01837849"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Nantong University", 
            "investigator_full_name": "Haiyan PAN", 
            "investigator_title": "associate chief physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Changes in New York Heart Association (NYHA) Class from Baseline to Day 5 after Treatment", 
                "safety_issue": "No", 
                "time_frame": "baseline and 5 days"
            }, 
            {
                "measure": "Blood Pressure (mmHg)", 
                "safety_issue": "No", 
                "time_frame": "baseline and 5 days"
            }, 
            {
                "measure": "Heart Rate", 
                "safety_issue": "No", 
                "time_frame": "baseline and 5 days"
            }, 
            {
                "measure": "Plasma Creatinine", 
                "safety_issue": "No", 
                "time_frame": "baseline and 5 days"
            }
        ], 
        "source": "Nantong University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nantong University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}